GlassScriptPhysician profile
James Christian Biesinger
NPI 1205885472
$10,500.16
in general payments reported to CMS, 2019-2025
29 companies · $3,171 in 2025
The $3,171 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,203 · 2022: $1,604 · 2023: $1,709 · 2024: $2,814 · 2025: $3,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,616 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,616.45 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,305.68 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,284.48 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $904.68 | 2021-2025 | Tremfya, Stelara, Simponi |
| Aimmune Therapeutics, INC. | $656.61 | 2024-2025 | Zenpep, Vowst |
| Pfizer INC. | $611.92 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $560.65 | 2021-2025 | Relistor, Trulance, Xifaxan |
| Phathom Pharmaceuticals, INC. | $493.78 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $428.08 | 2021-2023 | |
| Ardelyx, INC. | $377.27 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $337.42 | 2022-2025 | Dupixent |
| Celgene Corporation | $227.50 | 2022-2023 | Zeposia |
| Madrigal Pharmaceuticals | $210.01 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $201.48 | 2021-2025 | |
| Celltrion USA INC. | $188.50 | 2025 | Vegzelma |
| Genzyme Corporation | $109.18 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $102.45 | 2021-2023 | Injectafer |
| Fresenius Kabi USA, LLC | $71.41 | 2023 | Idacio |
| Braintree Laboratories, INC. | $64.17 | 2021-2023 | Suflave |
| Redhill Biopharma INC. | $62.71 | 2022 | |
| Novo Nordisk INC | $44.89 | 2025 | Wegovy |
| Lilly USA, LLC | $44.72 | 2023-2025 | Omvoh, Jardiance |
| Qol Medical, LLC | $44.64 | 2021-2025 | Sucraid |
| Ferring Pharmaceuticals INC. | $37.95 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $34.26 | 2025 | Iqirvo |
| Orphalan INC | $30.72 | 2025 | Cuvrior |
| Mylan Institutional INC. | $21.09 | 2023 | |
| Seqirus USA INC | $15.15 | 2022 | |
| Capsovision, INC. | $14.70 | 2025 | Capsocam Plus |
| Organon LLC | $14.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Biesinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.